The French drugmaker will acquire all outstanding shares of Translate Bio for $38 per share, representing a total value of about $3.2 billion.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi CEO Paul Hudson said in a news release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space.”
Mr. Hudson also said Sanofi is seeking to apply mRNA technology to areas other than vaccines, such as immunology, oncology and rare diseases.
Sanofi’s plans to acquire Translate Bio come a month after the drugmaker announced it will invest $476 million each year in its new mRNA Center of Excellence.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.